Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Net Margin: 2021-2025

Historic Net Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -105.81%.

  • Rhythm Pharmaceuticals' Net Margin rose 2943.00% to -105.81% in Q3 2025 from the same period last year, while for Sep 2025 it was -113.41%, marking a year-over-year increase of 11901.00%. This contributed to the annual value of -203.32% for FY2024, which is 3520.00% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Net Margin stood at -105.81% for Q3 2025, which was down 6.96% from -98.93% recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Net Margin registered a high of 125,000.00% during Q1 2021, and its lowest value of -12,915.69% during Q2 2021.
  • For the 3-year period, Rhythm Pharmaceuticals' Net Margin averaged around -214.22%, with its median value being -155.39% (2025).
  • Data for Rhythm Pharmaceuticals' Net Margin shows a peak YoY increase of 1,242,130bps (in 2022) and a maximum YoY decrease of 12,850,674bps (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Net Margin stood at -2,798.84% in 2021, then surged by 231,542bps to -483.42% in 2022, then skyrocketed by 31,163bps to -171.80% in 2023, then skyrocketed by 6,510bps to -106.70% in 2024, then soared by 2,943bps to -105.81% in 2025.
  • Its last three reported values are -105.81% in Q3 2025, -98.93% for Q2 2025, and -155.39% during Q1 2025.